sector medic suppli devic
 impress book plenti
came pt reiter buy
messag full sale came higher earlier
pre-announce rise yoy top consensu cap truli
impress compani revenu grew ebitda margin
expand expect repeat perform probabl
unrealist believ long growth runway front cgm adopt
continu ramp within insulin intens popul compani begin
branch patient group rais pt
reiter buy rate
close anoth impress year total revenu rose yoy
beat consensu compani busi maintain momentum
quarter sale top street expect mark
compani ninth consecut quarter strong gain domest growth
deceler remark level saw would note
yoy comp also point tougher manag estim finish
activ user global doubl report end
yoy math lower revenu per patient off-set
growth compani transit pharmaci channel manag estim
price headwind close forecast addit
pressur year yet volum gain made lost sale
cgm well way becom standard care insulin intens diabet
meanwhil continu lay groundwork cgm adopt outsid
insulin intens popul earlier year compani report result
pilot studi non-intens type patient show cgm use result
annual cost save system rel tradit finger stick
busi model patient group still well-defin increasingli optimist
opportun reflect model could begin meaning part
stori next coupl year long-term pipelin initi gestat
diabet glucos monitor icu remain earli today also hold great promis
view posit compani sustain momentum mani year come
continu make stride intern front well ou revenu
beat grew impress cc product level basi global
sensor sale came consensu hardwar sale
mix transmitt top street expect receiv
miss expect hardwar growth continu lag behind
sensor go forward medicar patient becom bigger part busi
promot broader access hardwar rebat pharmaci channel
long-term transit featur integr sensor/transmitt
fulli dispos increas use mobil app rather dedic receiv
like put addit pressur hardwar compon busi
impress top line perform stori quickli
becom revenu growth second quarter row
compani abl drive meaning oper leverag oper margin
expand nearli yoy come well ahead consensu forecast
achiev improv profit despit gross margin top
street estim actual come higher expect
well-contain sg provid boost although expect spend pick
bit manag invest support futur growth progress compani
made date suggest us could approach goal oper
margin much sooner expect manag guidanc strike
us potenti conserv
page analyst certif import disclosur
revenu guidanc look beatabl well view manag reiter
guidanc sale impli growth ex-fx would
repres sharp deceler cc gain post believ
deceler like comp get tougher rapid influx new cgm patient
saw across entir market moder howev outlook still look
conserv us backdrop continu roll-out medicar patient
got access octob import new product launch partner
insulin deliveri side much larger instal base compani time
last year model call post adjust ep yoy
total revenu cc compar prior estim
pipelin front eye manag still expect initi limit
launch next-gen sensor late year full roll-out follow
prepar begin enrol clinic trial although clear whether
data actual disclos fda approv compani also work
ensur abl scale manufactur capac rapidli especi
work hard past month keep demand
plenti came reiter buy model call grow
sale compound-annual-growth-rate combin improv profit believ
outlook warrant premium valuat rais price target
base previous multipl revis forward ntm
sale estim signific upsid potenti target current level
reiter buy rate
page analyst certif import disclosur
san diego ca base medic devic compani focus develop
continu glucos monitor cgm technolog aid treatment
manag diabet compani launch first cgm system st
follow recent fda approv new system sixth gener
cgm technolog last twelv year time led way
cgm grown world-wide market posit impact live
believ continu glucos monitor cgm way becom standard
care insulin-depend diabet nearli year sinc introduct
countless studi valid advantag cgm tradit point in-tim
blood glucos test reduc critic factor manag diabet
yet adopt technolog ramp slowli held back inconsist sensor accuraci
conveni qualiti life issu high increment cost therapi recent
advanc address mani histor drawback pave way rapidli
increas cgm penetr past two year
increasingli bullish long-term outlook cgm adopt
abil sustain leadership posit market best-in-class technolog coupl
improv patient access result sustain growth high end med-tech
sector model grow revenu compound-annual-growth-rate driven strong
underli market growth continu transit pharmaci channel
expans new intern market expect launch new autom
insulin deliveri technolog key technolog partner
valu primarili ev/sal basi use repres group small-
to-mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim current trade ntm
sale compar rang comp group rais pt
base previous multipl forward ntm sale
estim reiter buy rate
downsid risk rate includ unexpect deceler cgm market growth
recent penetr gain greater anticip adopt competit cgm
technolog increment price pressur reduc sale margin
clinic regulatori setback key pipelin program particular sensor
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
revenu compon
compani report guggenheim secur llc estim
page analyst certif import disclosur
